Governance of the concentration of plasma LDL: A reevaluation of the LDL receptor paradigm

Atherosclerosis

Volumn 148, Issue 2, 2000, Pages 215-229

  Sniderman, Allan D ^a   Zhang, Xiao Jing ^a   Cianflone, Katherine ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Cholesterol; Familial hypercholesterolemia; Plasma LDL

Indexed keywords

APOLIPOPROTEIN B100; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; SITOSTEROL;

CARDIOVASCULAR RISK; CHOLESTEROL ESTER STORAGE DISEASE; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIVER; MODEL; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEROL METABOLISM;

ANIMALS; CHOLESTEROL; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS, LDL; LIVER; MODELS, CARDIOVASCULAR; OSMOLAR CONCENTRATION; RECEPTORS, LDL; STEROLS;

EID: 0033955791     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00282-8     Document Type: Article

References (132)

1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 participants with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
2. Sacks F.M., Pfeffer M., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335:1996;1001-1009.
3. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
4. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. J Am Med Assoc 1998;279:1615-1622.
5. Goldstein J.L., Kita T., Brown M.S. Defective lipoprotein receptors and atherosclerosis. N. Engl. J. Med. 309:1983;288-296.
6. Brown M.S., Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science. 232:1986;34-47.
7. Goldstein J.L., Brown M.S. Familial hypercholesterolemia. Scriver C.R., Beaudet A.L., Sly W.S., Valle D. The Metabolic Basis of Inherited Disease. 6th edition:1989;1215-1250 McGraw-Hill, New York.
8. Soria L.F., Ludwig E.H., Clarke H.R.G., Vega G.L., Grundy S.M., McCarthy B.J. Association between a specific apolipoprotein B mutation and familal defective apolipoprotein B-100. Proc. Natl. Acad. Sci. USA. 86:1988;587-591.
9. Fisher W.R., Zech L.A., Stacpoole P.W. ApoB metabolism in familial hypercholesterolemia: inconsistencies with the LDL receptor paradigm. Arterioscler. Thromb. 14:1994;501-510.
10. Dietschy J.M., Kita T., Suckling K.E., Goldstein J.L., Brown M.S. Cholesterol synthesis in vivo and in vitro in the WHHL rabbit, an animal with defective low density lipoprotein receptors. J. Lipid Res. 24:1983;469-480.
11. Hoeg J.M., Demosky S.J. Jr, Schaefer E.J., Starzi T.E., Brewer H.B. Jr Characterization of hepatic low density lipoprotein binding and cholesterol metabolism in normal and homozygous familial hypercholesterolemic subjects. J. Clin. Invest. 3:1984;429-436.
12. Stacpoole P.W., Bridge D.M., Alvarez I.M., Goldberg R.B., Harwood H.J. Jr In vivo regulation of human mononuclear leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: decreased enzyme catalytic efficiency in familial hypercholesterolemia. J. Clin. Invest. 80:1987;1401-1408.
13. Thompson G.R., Naoumova R.P., Watts G.F. Role of cholesterol in regulating apolipoprotein B secretion by the liver. J. Lipid Res. 37:1996;439-447.
14. Brown M.S., Goldstein J.L. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 89:1997;331-340.
15. Gregg R.E., Wetterau J.R. The molecular basis of abetalipoproteinemia. Curr. Opin. Lipidol. 5:1994;81-86.
16. Jamil H., Gordon D.A., Eustice D.C., Brooks C.M., Dickson J.K. Jr, Chen Y. et al. An inhibitor of microsomal triglyceride transfer protein inhibits apoB secretion from HepG2 cells. Proc. Natl. Acad. Sci. USA. 93:1996;11991-11995.
17. Haghpassand M., Wilder D., Moberly J.D. Inhibition of apolipoprotein B and triglyceride secretion in human hepatoma cells (HepG2). J. Lipid Res. 37:1996;1468-2480.
18. Jamil H, Chu C-H, Dickson JK Jr, Chen Y, Yan M, Biller SA, Gregg RE, Wetterau R, Gordon DA. Evidence that microsomal triglyceride transfer protein is limiting in the production of apolipoprotein B-containing lipopoproteins in hepatic cells. J Lipid Res 1998;39:1448-1454.
19. Stone B.G., Schreiber D., Alleman L.D., Ho C.-Y. Hepatic metabolism and secretion of a cholesterol enriched lipoprotein fraction. J. Lipid Res. 28:1987;162-172.
20. Mitropoulos K.A., Venkatesan S., Reeves B.E., Balasubramaniam S. Modulation of 3-hydroxy-3-methylglutaryl-CoA reductase and acyl-CoA:cholesterol acyltransferase by the transfer of nonesterified cholesterol to rat liver microsomal vesicles. J. Biochem. 194:1981;265-271.
21. Mitropolous K.A., Balasubramaniam S., Venkatesan S., Reeves B.E. On the mechanism for the regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, of cholesterol 7α-hydroxylase and of acyl-coenzyme A: cholesterol acyltransferase by free cholesterol. Biochim. Biophys. Acta. 530:1978;99-111.
22. Stone B.G., Evans C.D., Fadden R.J., Schreiber D. Regulation of hepatic cholesterol ester hydrolase and acyl-coenzyme A:cholesterol acyltransferase in the rat. J. Lipid Res. 30:1989;1681-1690.
23. Cummings M.H., Watts G.F., Pal C., Umpleby M., Hennessy T.R., Naoumova R., Sönksen P.H. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in obesity: a stable isotope study. J. Clin. Sci. 88:1995;225-233.
24. Cummings M.H., Watts G.F., Umpleby A.M., Hennessy T.R., Naoumova R., Slavin B.M., Thompson G.R., Sönksen P.H. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetologia. 38:1995;959-967.
25. Watts G.F., Naoumova R., Cummings M.H., Umpleby A.M., Slavin B.M., Sönksen P.H., Thompson G.R. Direct correlation between cholesterol synthesis and hepatic secretion of apolipoprotein B-100 in normolipidemic subjects. Metabolism. 44:1995;1052-1057.
26. Watts G.F., Cummings M.H., Umpleby M., Quiney J.R., Naoumova R., Thompson G.R., Sönksen P.H. Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolemia: pathophysiological and therapeutic implications. Eur. J. Clin. Invest. 25:1995;559-567.
27. Watts GF, Naoumova R, Kelly JM, Riches FM, Croft KD, Thompson GR. Inhibition of cholesterogenesis decreases hepatic secretion of apoB-100 in normolipidemic subjects. Am J Physiol 1997;273:E462-470.
28. Kohen Avramoglu R., Cianflone K., Sniderman A.D. Role of the neutral lipid accessible pool in the regulation of secretion of apoB-100 lipoprotein particles by HepG2 cells. J. Lipid Res. 36:1995;2513-2528.
29. Cianflone K., Yasruel Z., Rodriguez M.A., Vas D., Sniderman A.D. Regulation of apoB secretion from HepG2 cells: evidence for a critical role for cholesterol ester synthesis in the response to a fatty acid challenge. J. Lipid Res. 31:1990;2045-2055.
30. Cianflone K., Dahan S., Monge J.C., Sniderman A.D. Pathogenesis of carbohydrate-induced hypertriglyceridemia using HepG2 cells as a model system. Arterioscler. Thromb. Vasc. Biol. 12:1992;271-277.
31. Fuki I.V., Preobrazhensky S.N., Misharin A.Y., Bushmakina N.G., Menschikov G.B., Repin V.S., Karpov R.S. Effect of cell cholesterol content on apolipoprotein B secretion and LDL receptor activity in the human heptoma cell line, HepG2. Biochim. Biophys. Acta. 1001:1989;235-238.
32. Dashti N. The effect of low density lipoproteins, cholesterol, and 25-hydroxycholesterol on apolipoprotein B gene expression in HepG2 cells. J. Biol. Chem. 267:1992;7160-7169.
33. Craig W.Y., Cooper A.D. Effects of chylomicron remnants and beta-VLDL on the class and composition of newly secreted lipoproteins by HepG2 cells. J. Lipid Res. 29:1988;299-308.
34. Craig W.Y., Nutik R., Cooper A.D. Regulation of apoprotein synthesis and secretion in the human hepatoma HepG2. The effect of exogenous lipoprotein. J. Biol. Chem. 263:1988;13880-13890.
35. Fungwe T.V., Cagen L., Wilcox H.G., Heinberg M. Regulation of hepatic secretion of very low density lipoprotein by dietary cholesterol. J. Lipid Res. 33:1992;179-191.
36. Musanti R., Giorgini L., Lovisolo P., Pirillo A., Chiari A., Ghiselli G. Inhibition of acyl-coA: cholesterol acyltransferase decreases apolipoprotein B-100-containing lipoprotein secretion from HepG2 cells. J. Lipid Res. 37:1996;1-14.
37. Tanaka M., Jingami H., Otani H., Cho M., Ueda Y., Arai H., Nagano Y., Doi T., Yokode M., Kita T. Regulation of apolipoprotein B production and secretion in response to the change of intracellular cholesteryl ester contents in rabbit. J. Biol. Chem. 268:1993;12713-12718.
38. Tanaka M., Otani H., Yokode M., Kita T. Regulation of apolipoprotein B secretion in heptocytes from Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Atherosclerosis. 114:1995;73-82.
39. Kosykh V.A., Preobrazhensky S.N., Fuki I.V., Zaikina O.E., Tsibulsky V.P., Repin V.S., Smirnov V.N. Cholesterol can stimulate secretion of apolipoprotein B in cultured human hepatocytes. Biochim. Biophys. Acta. 836:1985;385-389.
40. Carr T.P., Hamilton R.L. Jr, Rudel L.L. ACAT inhibitors decrease secretion of cholesteryl esters and apolipoprotein B by perfused livers of African green monkeys. J. Lipid Res. 36:1995;25-36.
41. Krause B.R., Pape M.E., Kieft K., Auerbach C.L., Bisgaier R., Homan R.S. Newton ACAT inhibition decreases LDL cholesterol in rabbits fed a cholesterol-free diet. Marked changes in LDL cholesterol without changes in LDL receptor mRNA abundance. Arterioscler. Thromb. Vasc. Biol. 14:1994;598-604.
42. Krause B.R., Anderson M., Bisgaier C.L., Bocan T., Bousley R., Dehart P., Essenburg A., Hamelehle K., Homan R., Kieft K., McNally W., Stanfield R., Newton R.S. In vivo evidence that the lipid-regulating activity of the ACAT inhibitor CI-976 in rats is due to inhibition of both intestinal and liver ACAT. J. Lipid Res. 34:1993;279-294.
43. Huff M.W., Telford D.E., Barrett P.H.R., Bilheimer J.T., Gillies P.J. Inhibition of hepatic ACAT decreases apoB secretion in miniature pigs fed a cholesterol-free diet. Arterioscler. Thromb. Vasc. Biol. 14:1994;1498-1508.
44. Sugiyama Y., Odaka H., Itokawa S., Ishikawa E., Tomari Y., Ikeda H. TMP-153, a novel ACAT inhibitor, lowers plasma cholesterol through its hepatic action in Golden hamsters. Atherosclerosis. 118:1995;145-153.
45. Goh E.H., Heimberg M. Relationship between activity of hepatic 3-hydroxy-3-methylglutaryl-coenzyme A reductase and secretion of very-low-density-lipoprotein cholesterol by the isolated perfused liver and in the intact rat. J. Biochem. 184:1979;1-6.
46. Huff M.W., Telford D.E. Regulation of low density lipoprotein apoprotein B metabolism by lovastatin and cholestyramine in miniature pigs: effects on LDL composition and synthesis of LDL subfractions. Metabolism. 38:1989;256-264.
47. Huff M.W., Telford D.E., Barrett P.H.R. Dietary fish oil plus lovastatin decreases both VLDL and LDL apoB production in miniature pigs. Arterioscler. Thromb. Vasc. Biol. 12:1992;902-910.
48. Kasim S.E., Leboeuf R.C., Khilnani S., Tallapaka L., Dayananda D., Jen K.L.C. Mechanisms of triglyceride-lowering effect of an HMG-CoA reductase inhibitor in a hypertriglyceridemic animal model, the Zucker obese rat. J. Lipid Res. 33:1992;1-7.
49. Auerbach B.J., Krause B.R., Bisgaier C.L., Newton R.S. Comparative effects of HMG-CoA reductase inhibitors on apoB production in the casein-fed rabbit: atorvastatin versus lovastatin. Atherosclerosis. 15:1995;173-180.
50. Conde K., Vergara-Jiminez M., Krause B.R., Newton R.S., Fernandez M.L. Hypocholesterolemic actions of atorvatatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig. J. Lipid Res. 37:1996;2372-2382.
51. Burnett J.R., Wilcox L.J., Telford D.E., Kleinstiver S.J., Hugh P., Barrett P.H.R., Newton R.S., Huff M.W. Inhibition of HMG-CoA Reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs. Arterioscler. Thromb. Vasc. Biol. 17:1997;2589-2600.
52. Burnett J.R., Wilcox L.J., Telford D.E., Kleinstiver S.J., Barrett P.H., Huff M.W. Inhibition of cholesterol esterification by DuP 128 decreases hepatic apolipoprotein B secretion in vivo: effect of dietary fat and cholesterol. Biochim. Biophys. Acta. 1393:1998;63-79.
53. Arad Y., Ramakrishnan R., Ginsberg H.N. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production. J. Lipid Res. 31:1990;567-582.
54. Arad Y., Ramakrishnan R., Ginsberg H.N. Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. Metabolism. 41:1992;487-493.
55. Cortner J., Bennet M.J., Le N.A., Coates P.M. The effect of lovastatin on very-low-density lipoprotein B production by the liver in familial combined hyperlipidemia. J. Inherit. Metab. Dis. 16:1993;127-134.
56. Vega G.L., East C., Grundy S.M. Lovastatin therapy in familial dysbetalipoproteinemia: effects on the kinetics of apolipoprotein B. Atherosclerosis. 70:1988;131-143.
57. Ginsberg H.N., Le N.A., Short M.P., Ramakrishnan R., Desnick R.J. Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis. J. Clin. Invest. 80:1987;1692-1697.
58. Hirano T., Kumuro F., Furukawa S., Nagano S., Takahashi T. Effect of pravastatin sodium, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on very-low-density lipoprotein composition and kinetics in hyperlipidemia associated with experimental nephrosis. Metabolism. 39:1990;605-609.
59. Cuchel M., Schaefer E.J., Millar J.S., Jones P.J.H., Dolnikowski G.G., Vergani C., Lichtenstein A.H. Lovastatin decreases de novo cholesterol synthesis and LDL apoB-100 production rates in combined-hyperlipidemic males. Arterioscler. Thromb. Vasc. Biol. 17:1997;1910-1917.
60. Kvilekval K., Lin J., Cheng W., Abumrad N. Fatty acids as determinants of triglyceride and cholesteryl ester synthesis by isolated hepatocytes: kinetics as a function of various fatty acids. J. Lipid Res. 35:1994;1786-1794.
61. Havekes L.M., de Wit E.C.M., Princen H.M.G. Cellular free cholesterol in Hep G2 cells is only partially available for down-regulation of low-density-lipoprotein receptor activity. Biochem. J. 247:1987;739-746.
62. Havekes L.M., Verboom H., de Wit E.C.M., Yap S.H., Princen H.M. Regulation of low density lipoprotein receptor activity in primary cultures of human hepatocytes by serum lipoproteins. Hepatology. 6:1986;1356-1360.
63. Huff M.W., Carroll K.K. Effects of dietary protein on turnover, oxidation, and absorption of cholesterol and on steroid secretion in rabbits. J. Lipid Res. 21:1980;546-558.
64. Kuyvenhoven M.W., West C.E., Van der Meer R., Beynen A.C. Fecal steroid excretion in relation to the development of casein-induced hypercholesterolemia in rabbits. J. Nutr. 116:1986;1395-1404.
65. Chao Y.-S., Yamin T.-T., Alberts A.W. Effects of cholestyramine on low density lipoprotein binding sites on liver membranes from rabbits with endogenous hypercholesterolemia induced by a wheat starch-casein diet. J. Biol. Chem. 1986:257;3623-3627.
66. Kozarsky K.F., Donahee M.H., Rigotti A., Labal S.N., Edelman E.R., Kreiger M. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature. 387:1997;414-417.
67. Ikewaki K., Nishiwaki M., Sakamoto T., Ishikawa T., Fairwell T., Zech L.A., Nakamura H., Brewer H.B., Rader D.J. Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency. J. Clin. Invest. 96:1995;1573-1581.
68. Soutar A.K., Myant N.B., Thompson G.R. The metabolism of very low density and intermediate density lipoprotein in patients with familial hypercholesterolaemia. Atherosclerosis. 43:1982;217-231.
69. Janus E.D., Nicoll A.M., Turner P.R., Magill P., Lewis B. Kinetic bases of the primary hyperlipideamias: studies of apolipoprotein B turnover in genetically defined subjects. Eur. J. Clin. Invest. 10:1980;161-172.
70. Teng B., Sniderman A.D., Soutar A.K., Thompson G.R. Metabolic bases of hyperapobetalipoproteinmia. Turnover of apolipoprotein B in low density lipoprotein and its precursors and subfractions compared with normal and familial hypercholesterolemia. J. Clin. Invest. 77:1986;663-672.
71. 3H]leucine tracer. J. Lipid Res. 32:1992;1823-1836.
72. Bilheimer D.W., Grundy S.M., Brown M.S., Goldstein J.L. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc. Natl. Acad. Sci. USA. 80:1983;4124-4128.
73. Shepherd J., Packard C.J., Bicker S., Lawrie V., Gemmell Morgan H. Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. N. Engl. J. Med. 302:1980;1219-1222.
74. Reihner E., Rudling M., Stahlberg D., Berglund L., Ewerth S., Bjorkhem I., Einarsson K., Angelin B. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N. Engl. J. Med. 323:1990;224-228.
75. Gaw A., Packard C.J., Murray E.F., Lindsay G.M., Griffin B.A., Caslake M.J., Vallance B.D., Lorimer A.R., Shepherd J. Effects of simvastatin on apoB metabolism and LDL subfraction distribution. Arterioscler. Thromb. 13:1993;170-189.
76. Aguilar-Salinas C.A., Barret P.H.R., Kelber J., Delmez J., Schonfeld G. Physiologic mechanisms of action of lovastatin in nephrotic syndrome. J. Lipid Res. 36:1995;188-199.
77. Packard C.J., Munro A., Lorimer A.R., Gotto A.M., Shepherd J. Metabolism of apoliprotein B in large triglyceride-rich very low density lipoproteins of normal and hypertriglyceridemic subjects. J. Clin. Invest. 74:1984;2178-2192.
78. Cummings M.H., Wattts G.F., Umpleby M., Hennessy T.R., Quiney J.R., Sönksen P.H. Increased hepatic secretion of very-low-density-lipoproein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: a stable isotope study. Atherosclerosis. 113:1995;79-89.
79. Zulewski H., Nimmis R., Miserez A.R., Baumstark M.W., Keller U. VLDL and IDL apoplipoprotein B-100 kinetics in familial hypercholesterolemia due to impaired LDL receptor function or to defective apolipoprotein B-100. J. Lipid Res. 39:1998;380-387.
80. Marais A.D., Naoumova R.P., Firth J.C., Penny C., Neuwirth C.K., Thompson G.R. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozyogous familial hypercholesterolemia. J. Lipid Res. 38:1997;2071-2078.
81. Raal F., Pilcher G.J., Illingworth D.R., Pappu A.S., Stein E.A., Laskarzewski P., Mitchel Y.B., Melin M.R. Expanded-dose simvastatin is effective in homozyogous familial hypercholesterolaemia. Atherosclerosis. 135:1997;249-256.
82. Couture P., Gaudet D., Brun D., Bergeron J., Cantin L., Black D. et al. Effect of atorvastatin on serum levels of lipoproteins in French Canadians with homozygous or compound heterozygous familial hypercholesterolemia. Atherosclerosis. 134:1997;54.
83. Bisgaier C.L., Essenburg A.D., Auerbach B.J., Pape M.E., Sekerke C.S., Gee A., Wölle S., Newton R.S. Attenuation of plasma low density lipoprotein cholestesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors. J. Lipid Res. 38:1997;2502-2515.
84. Shiomi M., Shiraishi M., Yata T., Ito T. Effect of fluvastatin sodium on secretion of very low density lipoprotein and serum cholesterol levels. Drug Res. 44:1994;1154-1156.
85. Mohammadi A., Macri J., Newton R., Romain T., Dulay D., Adeli K. Effect of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells. Arterioscler. Thromb. Vasc. Biol. 18:1998;783-793.
86. Stacpoole P.W., von Bergmann K., Kilgore L.L., Zech L.A., Fisher W.R. Nutritional regulation of cholesterol synthesis and apolipoprotein B kinetics: studies in patients with familial hypercholesterolemia and normal subjects treated with a high carbohydrate, low fat diet. J. Lipid Res. 32:1991;1837-1848.
87. Stacpoole P.W., Harwood H.J. Jr, Varnado C.E. Dietary carbohydrate decreases 3-hydroxy-3-methyl-glutaryl coenzyme A reductase activity and cholesterol synthesis in rat liver. Biochem. Biophys. Res. Commun. 113:1983;888-894.
88. Dietschy J.M., Kita T., Suckling K.E., Goldstein J.L., Brown M.S. Cholesterol synthesis in vivo and in vitro in the WHHL rabbit, an animal with defective low density lipoprotein receptors. J. Lipid Res. 24:1983;469-480.
89. Salen G., Shefer S., Nguyen L., Ness G.C., Tint G.S., Shore V. Sitosterolemia. J. Lipid Res. 33:1992;945-955.
90. Salen G., Shore V., Tint G.S., Forte T., Shefer S., Horak I., Horak E., Dayal B., Nuguyen L., Batta A.K., Lindgren F.T., Kwiterovich P.O. Jr Increased sitosterol absorption, decreased removal, and expanded body pools compensate for reduced cholesterol synthesis in sitosterolemia with xanthomatosis. J. Lipid Res. 30:1989;1319-1330.
91. Miettinen T.A. Phytosterolemia, xanthomatosis and premature atherosclerotic arterial disease: a case with high plant sterol absorption, impaired sterol elimination and low cholesterol synthesis. Eur. J. Clin. Invest. 10:1980;27-35.
92. Nuguyen L, Shefer S, Salen G, Ness G, Tint GS, Zaki FG, Rani I. Molecular defect in cholesterol synthesis in sitosterolemia with xanthomatosis. J Clin Invest 1990;86:926-931.
93. Shefer S., Salen G., Nugyen L., Batta A.K., Packin V., Tint G.S., Hauser S. Competitive inhibition of bile acid synthesis by endogenous cholestanol and sitosterol in sitosterolemia with xanthomatosis. J. Clin. Invest. 82:1988;1833-1839.
94. Beil F.U., Vega G.L., Ma P.A., Gary A., Grundy S.M. Lipoprotein kinetics in beta sitosterolemia. J. Clin. Invest. 86:1990;926-931.
95. Nguyen L., Salen G., Shefer S., Shore V., Tint G.S., Ness G. Unexpected failure of bile acid malabsorption to stimulate cholesterol synthesis in sitosterolemia with xanthomatosis: comparison with lovastatin. Arteriosclerosis. 10:1990;289-297.
96. Nguyen L., Cobb M., Shefer S., Salen G., Ness G.C., Tint G.C. Regulation of cholesterol biosynthesis in sitosterolemia: effects of lovastatin, cholestyramine and dietary sterol restriction. J. Lipid Res. 32:1991;1941-1948.
97. Honda A., Salen G., Nugyen L.B., Tint G.S., Batta A.K., Shefer S. Down-regulation of cholesterol biosynthesis in sitosterolemia: diminished activities of acetoacetyl-CoA thiolase, 3-hydroxy-3-methylgluatryl-CoA synthase, reductase, squalene synthase, and 7-dehydrocholesterol 7-reductase in liver and mononuclear leukocytes. J. Lipid Res. 39:1998;44-50.
98. Assmann G., Fredrickson D.S. Acid lipase deficiency: Wolman's disease and cholesteryl ester storage deficiency. Stanbury J.B., Wyngaarden J.B., Fredrickson D.S., Goldstein J.L., Brown M.S. The Metabolic Basis of Inherited Diseases. 1992;803-819 McGraw-Hill, New York.
99. Goldstein J.L., Dana S.E., Faust J.R., Beaudet A.L., Brown M.S. Role of lysosomal acid lipase in the metabolism of plasma low density lipoprotein. J. Biol. Chem. 250:1975;8487-8795.
100. Dawson P.A., Metherall J.E., Ridgway N.D., Brown M.S., Goldstein J.L. Genetic distinction between sterol-mediated transcriptional and posttranscriptional control of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J. Biol. Chem. 266:1991;9128-9134.
101. Cummings M.H., Watts G.F. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in cholesteryl ester storage disease. Clin. Chem. 41:1995;111-114.
102. Levy R., Ostlund R.E. Jr, Schonfeld G., Wong P., Semenkovich C.F. Cholesteryl ester storage disease: complex molecular effects of chronic lovastatin therapy. J. Lipid Res. 33:1992;1005-1015.
103. DiBisceglie A.M., Ishak K.G., Rabin L., Hoeg J.M. Cholesteryl ester storage disease: hepatopathology and effects of therapy with lovastatin. Hepatology. 11:1990;764-772.
104. McCoy E., Yokoyama S. Treatment of cholesteryl ester storage disease with combined cholestyramine and lovastatin. Ann. NY Acad. Sci. 623:1991;453-454.
105. Tarantino M.C., McNamara D.J., Granstrom P., Ellefson R.D., Ungar E.C., Udall E.C. Jr Lovastatin therapy for cholesterol ester storage disease in two sisters. J. Pediatr. 118:1991;131-135.
106. Keys A., Anderson J.T., Grande F. Serum cholesterol response to changes in the diet. Metabolism. 14:1965;766-775.
107. Burslem J.L., Schonfeld G., Howald M.A., Weidman S.W., Miller J.P. Plasma apoprotein and lipoprotein lipid levels in vegetarians. Metabolism. 27:1978;711-719.
108. Schaefer E.J., Levy R.I., Ernst N.D., Van Sant F.D., Brewer H.B. The effects of low cholesterol, high polyunsaturated fat and low fat diets on plasma lipid and lipoprotein cholesterol levels in normal and hypercholesterolemic subjects. Am. J. Clin. Nutr. 34:1981;1758-1763.
109. Sniderman A.D., Zhang Z., Cianflone K. Divergent responses of the liver to increased delivery of glucose or fatty acids: implications for the pathogenesis of type IV hyperlipoproteinemia. Atherosclerosis. 137:1998;291-301.
110. Goh E.H., Heimberg M. Stimulation of hepatic cholesterol biosynthesis by oleic acid. Biochem. Biophys. Res. Commun. 55:1973;382-388.
111. Goh E.H., Heimberg M. Effects of free fatty acids on activity of hepatic microsomal 3-hydroxy-methylglutaryl coenzyme A reductase and on secretion of cholesterol and triglyceride by the liver. J. Biol. Chem. 252:1977;2822-2826.
112. Chait A., Albers J.J., Brunzell J.D. Very low density lipoprotein overproduction in genetic forms of hypertriglyceridemia. Eur. J. Clin. Invest. 10:1980;17-22.
113. Kissebah A.H., Alfarsi S., Evans D.J. Low density lipoprotein metabolism in familial combined hyperlipidemia. Mechanism of the multiple lipoprotein phenotypic expression. Arteriosclerosis. 4:1984;614-624.
114. Cortner J.A., Coates P.M., Bennett M.J., Cryer D.R., Le N.A. Familial combined hyperlipidemia: use of stable isotopes to demonstrate overproduction of very low-density lipoprotein apolipoprotein B by the liver. J. Inher. Metab. Dis. 14:1991;915-922.
115. Venkatesan S., Cullen P., Pacy P., Halliday D., Scott J. Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 13:1993;1110-1118.
116. Daumerie C.M., Woollett L.A., Dietschy J.M. Fatty acids regulate hepatic low density lipoprotein receptor activity through redistribution of intracellular cholesterol pools. Proc. Natl. Acad. Sci. USA. 89:1992;10797-10801.
117. Zhang Z, Cianflone K, Sniderman AD. The role of cholesterol ester mass in the regulation of secretion of apoB100 lipoprotein particles by hamster hepatocytes and the effects of statins on that relationship. Arterioscler Thromb Vasc Biol 1999 (in press).
118. Kushawaha R.S., Barrett P.H.R., Reardon C.A., Lewis D.S., Carey K.D., Getz G.S., Mcgill H.C. Jr Relationships of plasma and hepatic variables with rates of plasma low-density lipoprotein apolipoprotein B metabolism in baboons fed low- and high fat-diets. Metabolism. 44:1995;1058-1066.
119. Kesaniemi Y.A., Grundy S.M. Significance of low density lipoprotein production in the regulation of plasma cholesterol level in man. J. Clin. Invest. 70:1982;13-22.
120. Vega G.L., Denke M.A., Grundy S.M. Metabolic basis of primary hypercholesterolemia. Circulation. 84:1991;118-128.
121. Glatz J.F.C., Turner P.R., Katan M.B., Stalenhoef A.F., Lewis B. Hypo-and hyperresponse of serum cholesterol level and low density lipoprotein production and degradation to dietary cholesterol in man. Ann. NY Acad. Sci. 676:1993;163-179.
122. Packard CJ, Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb 1999;17:3542-3556.
123. f 20-60) in moderate hypercholesterolemia: relationships between apolipoprotein B kinetics and plasma lipoproteins. J. Lipid. Res. 136:1995;158-171.
124. Babirak S.P., Brown B.G., Brunzell J.D. Familial combined hyperlipidemia and abnormal lipoprotein lipase. Arterioscler. Thromb. Vasc. Biol. 13:1993;629-636.
125. Cianflone K., Maslowska M., Sniderman A.D. Impaired response of fibroblasts from patients with hyperapobetalipoproteinemia to acylation-stimulating protein. J. Clin. Invest. 85:1990;722-730.
126. Zhang X.-J., Cianflone K., Genest J., Sniderman A.D. Plasma acylation stimulating hormone (ASP) as a predictor of impaired cellular biologic response to ASP in patients with hyperapoB. Eur. J. Clin. Invest. 28:1998;730-739.
127. Goldstein J.L., Schrott H.G., Hazzard W.R., Bierman E.L., Motulsky A.G. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J. Clin. Invest. 52:1998;1544-1568.
128. Angelin B., Hershon K.S., Brunzell J.D. Bile acid metabolism in hereditary forms of hypertriglyceridemia: evidence for an increased synthesis rate in monogenic familial hypertriglyceridemia. Proc. Natl. Acad. Sci. USA. 84:1987;5434-5438.
129. Duane W.C. Abnormal bile acid absorption in familial hypertriglyceridema. J. Lipid Res. 36:1995;96-107.
130. Aguilar-Salinas C.A., Barrett H., Schonfeld G. Metabolic modes of action of the statins in the hyperlipoproteinemias. Atherosclerosis. 141:1998;201-207.
131. Cortner J.A., Bennet M.J., Le N.A., Coates P.M. The effect of lovastatin on very low density lipopoprotein apolipoprotein B production by the liver in familial combined hyperlipidemia. J. Inher. Metab. Dis. 16:1993;127-134.
132. Aguilar-Salinas C.A., Barrett P.H.R., Schonfeld G. Description of a kindred with familial combined hyperlipidemia with unusual kinetic abnormalities of the apolipoprotein B containing lipoproteins. Effects of pravastatin therapy. Arterioscler. Thromb. Vasc. Biol. 17:1997;72-82.